Halozyme Therapeutic (HALO)

$63.27 -0.38 (-0.60%)
Market Cap 7.51B
Revenue (ttm) 1.40B
Net Income (ttm) 316.89M
EPS (ttm) N/A
PE Ratio 17.23
Forward PE 8.43
Profit Margin 22.69%
Debt to Equity Ratio 43.90
Volume 1,422,800
Avg Vol 1,861,482
Day's Range N/A - N/A
Shares Out 118.02M
Stochastic %K 11%
Beta 0.98
Analysts Sell
Price Target $82.50

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
ISmokeMoney
ISmokeMoney Mar. 18 at 10:31 PM
$HALO $58 by Friday
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 17 at 8:44 PM
$HALO Share Price: $65.13 Contract Selected: Sep 18, 2026 $65 Calls Buy Zone: $5.02 – $6.20 Target Zone: $9.34 – $11.42 Potential Upside: 76% ROI Time to Expiration: 184 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
draketdot
draketdot Mar. 17 at 4:28 AM
$HALO back to ath. Wedge formed. Give it 1-2months
0 · Reply
Sean29md
Sean29md Mar. 16 at 9:50 PM
$HALO https://www.press9.kr/news/articleView.html?idxno=73491#:~:text=According%20to%20court%20filings%2C%20Halozyme,play%20a%20critical%20role%20in
0 · Reply
Doozio
Doozio Mar. 14 at 5:01 PM
$QQQ that monthly Mac D…….. da $HALO is bent. It ain’t broken. Yet…..
1 · Reply
ISmokeMoney
ISmokeMoney Mar. 12 at 10:02 PM
$HALO let it go. This will hit 50 before it hits 80 again
1 · Reply
Sean29md
Sean29md Mar. 12 at 1:10 PM
$HALO This is what Helen was talking about when she said Alt-B4 and MDASE are identical (see attached)
1 · Reply
Sean29md
Sean29md Mar. 10 at 7:18 PM
$HALO Great presentation by Helen today: https://ir.halozyme.com/events-and-presentations/events/default.aspx
0 · Reply
Sean29md
Sean29md Mar. 9 at 3:42 PM
$HALO $HIMS Look at HIMS stock today (up 40%) after Novo Nordisk and HIMS dropped the legal battle and partnered up. Imagine what happens to Halo stock when Merck and Halozyme drop their patent fight and sign a licensing deal. Feeding all the court (US and Europe) and PTAB filling into Gemini, Claude, Grok and ChatGPT, all 4 AI platforms conclude that a licensing deal is the most likely outcome for Halozyme vs Merck. In the meantime enjoy buying halo at 2026 estimated PE of 8, over 70% profit margins and greater than 30% CAGR in EPS.
1 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:26 PM
$HALO Halozyme Therapeutics Inc. (NASDAQ: HALO) is gaining renewed investor attention as analysts raise price targets and highlight strong growth potential from its ENHANZE drug delivery platform. With partnerships tied to blockbuster therapies like Darzalex and Vyvgart, HALO stock is increasingly being viewed as one of the most intriguing cheap biotech stocks with recurring royalty revenue and long-term biotech innovation potential. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-invest-in-halozyme-therapeutics-halo/
0 · Reply
Latest News on HALO
Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Mar 12, 2026, 8:30 AM EDT - 7 days ago

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript

Mar 11, 2026, 1:22 PM EDT - 8 days ago

Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript

Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 10, 2026, 3:00 PM EDT - 9 days ago

Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Mar 6, 2026, 8:00 AM EST - 13 days ago

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 8:52 PM EST - 16 days ago

Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Halozyme to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:30 AM EST - 22 days ago

Halozyme to Participate in Upcoming Investor Conferences

Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge

Feb 18, 2026, 10:02 AM EST - 4 weeks ago

Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript

Feb 17, 2026, 8:24 PM EST - 4 weeks ago

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Feb 17, 2026, 4:01 PM EST - 4 weeks ago

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 10, 2026, 4:05 PM EST - 5 weeks ago

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth

Feb 2, 2026, 11:43 PM EST - 6 weeks ago

Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript

Jan 28, 2026, 12:12 PM EST - 7 weeks ago

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Jan 28, 2026, 6:30 AM EST - 7 weeks ago

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Jan 20, 2026, 4:05 PM EST - 2 months ago

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Jan 8, 2026, 8:00 AM EST - 2 months ago

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 2 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Dec 18, 2025, 7:00 AM EST - 3 months ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)

Dec 15, 2025, 4:06 AM EST - 3 months ago

Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)

Jim Lang Elected to Halozyme's Board of Directors

Dec 8, 2025, 4:05 PM EST - 3 months ago

Jim Lang Elected to Halozyme's Board of Directors

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Dec 4, 2025, 2:22 PM EST - 3 months ago

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Dec 4, 2025, 1:26 PM EST - 3 months ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 3:43 PM EST - 3 months ago

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 4 months ago

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Nov 18, 2025, 8:50 AM EST - 4 months ago

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

Nov 17, 2025, 7:00 AM EST - 4 months ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUS

The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 4 months ago

The Big 3: OKLO, HALO, V

OKLO V

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Nov 7, 2025, 8:30 AM EST - 4 months ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 6, 2025, 11:37 PM EST - 4 months ago

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 5, 2025, 4:05 PM EST - 4 months ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 8:16 PM EST - 4 months ago

Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Nov 3, 2025, 4:01 PM EST - 4 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Halozyme Just Bought Its Next Decade Of Growth

Oct 23, 2025, 1:17 PM EDT - 5 months ago

Halozyme Just Bought Its Next Decade Of Growth

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 21, 2025, 8:30 AM EDT - 5 months ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 10, 2025, 8:35 AM EDT - 5 months ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 3:22 PM EDT - 6 months ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:16 AM EDT - 6 months ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Oct 1, 2025, 7:00 AM EDT - 6 months ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:29 AM EDT - 6 months ago

Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Sep 4, 2025, 5:34 PM EDT - 7 months ago

Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 7 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 7 months ago

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 5:45 AM EDT - 8 months ago

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Aug 5, 2025, 4:01 PM EDT - 8 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 23, 2025, 11:36 AM EDT - 8 months ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 22, 2025, 8:30 AM EDT - 8 months ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Jul 14, 2025, 4:33 PM EDT - 8 months ago

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 9 months ago

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jun 20, 2025, 1:15 PM EDT - 9 months ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 28, 2025, 8:30 AM EDT - 10 months ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 11 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

ISmokeMoney
ISmokeMoney Mar. 18 at 10:31 PM
$HALO $58 by Friday
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 17 at 8:44 PM
$HALO Share Price: $65.13 Contract Selected: Sep 18, 2026 $65 Calls Buy Zone: $5.02 – $6.20 Target Zone: $9.34 – $11.42 Potential Upside: 76% ROI Time to Expiration: 184 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
draketdot
draketdot Mar. 17 at 4:28 AM
$HALO back to ath. Wedge formed. Give it 1-2months
0 · Reply
Sean29md
Sean29md Mar. 16 at 9:50 PM
$HALO https://www.press9.kr/news/articleView.html?idxno=73491#:~:text=According%20to%20court%20filings%2C%20Halozyme,play%20a%20critical%20role%20in
0 · Reply
Doozio
Doozio Mar. 14 at 5:01 PM
$QQQ that monthly Mac D…….. da $HALO is bent. It ain’t broken. Yet…..
1 · Reply
ISmokeMoney
ISmokeMoney Mar. 12 at 10:02 PM
$HALO let it go. This will hit 50 before it hits 80 again
1 · Reply
Sean29md
Sean29md Mar. 12 at 1:10 PM
$HALO This is what Helen was talking about when she said Alt-B4 and MDASE are identical (see attached)
1 · Reply
Sean29md
Sean29md Mar. 10 at 7:18 PM
$HALO Great presentation by Helen today: https://ir.halozyme.com/events-and-presentations/events/default.aspx
0 · Reply
Sean29md
Sean29md Mar. 9 at 3:42 PM
$HALO $HIMS Look at HIMS stock today (up 40%) after Novo Nordisk and HIMS dropped the legal battle and partnered up. Imagine what happens to Halo stock when Merck and Halozyme drop their patent fight and sign a licensing deal. Feeding all the court (US and Europe) and PTAB filling into Gemini, Claude, Grok and ChatGPT, all 4 AI platforms conclude that a licensing deal is the most likely outcome for Halozyme vs Merck. In the meantime enjoy buying halo at 2026 estimated PE of 8, over 70% profit margins and greater than 30% CAGR in EPS.
1 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:26 PM
$HALO Halozyme Therapeutics Inc. (NASDAQ: HALO) is gaining renewed investor attention as analysts raise price targets and highlight strong growth potential from its ENHANZE drug delivery platform. With partnerships tied to blockbuster therapies like Darzalex and Vyvgart, HALO stock is increasingly being viewed as one of the most intriguing cheap biotech stocks with recurring royalty revenue and long-term biotech innovation potential. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-invest-in-halozyme-therapeutics-halo/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 6 at 5:40 PM
$AUPH $BMRN $CPRX $HALO $HRMY Biotech stocks may be starting slow this year, but analysts believe the sector could be setting up for a powerful comeback. With massive pharmaceutical patent expirations approaching and over $1 trillion in industry capital ready for deals, these cheap biotech stocks could offer significant upside for investors searching for undervalued healthcare opportunities. https://biotechhealthx.com/biotech-news/10-cheap-biotech-stocks-to-buy-now/
0 · Reply
Sean29md
Sean29md Mar. 6 at 2:44 PM
$HALO 2026 PE is 8.71 and PEG is 0.27. Delicious! Enjoy. https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios
0 · Reply
NoobyDoo
NoobyDoo Mar. 5 at 10:14 PM
$HALO Got to the 200dma amidst this market uncertainty. Great buying opportunity to start, or add to a position. Need an HVAI deal announcement partnership sooner rather than later!!! C’mon Helen get it done!
0 · Reply
Sean29md
Sean29md Mar. 5 at 5:59 PM
$HALO executive officers and board members, it’s time for you to buy shares of Halozyme in open markets. Have a look at what the CEO of Berkshire Hathaway just did. https://www.cnbc.com/2026/03/05/berkshire-hathaway-begins-repurchasing-shares-ceo-greg-abel-buys-15-million-in-stock-.html
0 · Reply
Sean29md
Sean29md Mar. 5 at 4:35 PM
$HALO 2026 PE of 9.06. PEG of 0.28 (see link below)An 18% haircut since the recent high of $82.22. Buying hand over fist. Would like to see halozyme’s officers and board members buy in open markets too. https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios
1 · Reply
Sean29md
Sean29md Mar. 3 at 7:24 PM
$HALO Where is HVAI??? Come on Helen!
0 · Reply
Sean29md
Sean29md Mar. 3 at 6:08 PM
$HALO Helen had an excellent Q&A today at TD Cowen. You can here it here https://ir.halozyme.com/events-and-presentations/events/default.aspx
1 · Reply
JFDI
JFDI Mar. 2 at 5:30 PM
$HALO 69.69
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 2 at 3:07 PM
$HALO Share Price: $69.33 Contract Selected: Sep 18, 2026 $70 Calls Buy Zone: $5.95 – $7.35 Target Zone: $11.20 – $13.68 Potential Upside: 78% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Prester_John
Prester_John Feb. 25 at 5:14 PM
$HALO Nicest bunch of shorts I have encountered! WHAM down on open and then let one sell purchase higher later. Has been going on for days since earnings. I am not playing, just watching. They make just as much from the yo-yo and easier than if they try to drive it straight down.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 12:21 AM
$HALO Current Stock Price: $70.34 Contracts to trade: $70.0 HALO Mar 20 2026 Call Entry: $1.90 Exit: $2.96 ROI: 56% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
qpqpdbdb
qpqpdbdb Feb. 24 at 9:57 PM
$HALO Feels like 70 is the new 'base'. Was 60 before. Adding here and sell some on the way up to 80-90 range and holding some to sell if it blows past 90-100. Good luck everyone.
1 · Reply